Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC70	Torin1	3	72	sigmoid	sigmoid	HCC70 Torin1 0 3 72	8	2.415	3.74	0.495	0.279	0.0352	0.496	1.02	0.994	2.6e-07	NA	5.73	0.495	0.709	0.0284	0.498	1.06	0.994	2.26e-07	NA
HCC70	Torin2	1	72	sigmoid	sigmoid	HCC70 Torin2 0 1 72	8	1.364	0.0288	-0.732	0.772	0.183	-1.0	0.594	0.991	6.58e-07	NA	0.088	0.0644	0.539	0.088	0.0	0.622	0.988	1.95e-06	NA
HCC70	Torin2	2	72	sigmoid	sigmoid	HCC70 Torin2 0 2 72	8	1.826	0.0342	-0.522	0.671	0.401	-1.0	0.446	0.979	9.23e-06	NA	0.0639	0.0733	0.507	0.0639	0.0	0.462	0.969	2.98e-05	NA
HCC70	Torin2	3	72	sigmoid	sigmoid	HCC70 Torin2 0 3 72	8	2.425	0.076	-0.384	0.567	0.532	-0.933	0.541	0.988	1.88e-06	NA	0.0694	0.0576	0.51	0.0694	0.0	0.61	0.973	2.02e-05	NA
HCC70	Trametinib	1	72	sigmoid	sigmoid	HCC70 trametinib 0 1 72	8	1.421	0.015	0.339	0.521	0.00411	0.34	0.879	0.966	4.1e-05	NA	Inf	0.566	0.653	0.00373	0.566	0.875	0.968	3.23e-05	NA
HCC70	Trametinib	2	72	sigmoid	sigmoid	HCC70 trametinib 0 2 72	8	1.721	0.506	0.504	0.395	0.00469	0.467	0.581	0.944	0.000179	NA	Inf	0.612	0.687	0.00389	0.585	0.57	0.948	0.000138	NA
HCC70	Trametinib	3	72	sigmoid	sigmoid	HCC70 trametinib 0 3 72	8	2.463	Inf	0.56	0.361	0.00419	0.548	0.954	0.95	0.000123	NA	Inf	0.542	0.618	0.00342	0.533	0.965	0.958	7.33e-05	NA
HCC70	WYE-125132	1	72	sigmoid	sigmoid	HCC70 WYE-132 0 1 72	8	1.382	0.0518	0.346	0.418	0.0175	0.348	1.1	0.985	3.58e-06	NA	Inf	0.579	0.727	0.0165	0.579	1.09	0.983	4.63e-06	NA
HCC70	WYE-125132	2	72	sigmoid	sigmoid	HCC70 WYE-132 0 2 72	8	1.675	0.213	0.471	0.332	0.0211	0.467	1.18	0.996	6.89e-08	NA	Inf	0.598	0.744	0.0194	0.595	1.17	0.996	7.52e-08	NA
HCC70	WYE-125132	3	72	sigmoid	sigmoid	HCC70 WYE-132 0 3 72	8	2.417	Inf	0.592	0.246	0.0209	0.606	1.64	0.995	1.48e-07	NA	Inf	0.576	0.739	0.019	0.588	1.64	0.996	7.52e-08	NA
HCC70	ZSTK474	1	72	sigmoid	sigmoid	HCC70 ZSTK474 0 1 72	8	1.332	0.167	-0.265	0.366	0.201	-0.206	1.85	0.975	1.56e-05	NA	0.289	0.264	0.782	0.182	0.299	1.96	0.971	2.35e-05	NA
HCC70	ZSTK474	2	72	sigmoid	sigmoid	HCC70 ZSTK474 0 2 72	8	1.737	0.248	-0.0397	0.324	0.27	-0.0591	1.33	0.992	5.33e-07	NA	0.379	0.28	0.76	0.214	0.28	1.43	0.989	1.22e-06	NA
HCC70	ZSTK474	3	72	sigmoid	sigmoid	HCC70 ZSTK474 0 3 72	8	2.502	0.455	0.176	0.223	0.345	0.155	1.35	0.991	8.07e-07	NA	0.401	0.265	0.782	0.24	0.274	1.55	0.987	1.99e-06	NA
HCC1806	AS605240	1	72	sigmoid	sigmoid	HCC1806 AS-605240 0 1 72	8	2.728	Inf	0.911	0.0128	0.569	0.91	2.8	0.936	0.000262	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
HCC1806	AS605240	2	72	sigmoid	sigmoid	HCC1806 AS-605240 0 2 72	8	2.813	Inf	0.913	0.0124	0.569	0.913	2.8	0.936	0.000261	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
HCC1806	AS605240	3	72	sigmoid	sigmoid	HCC1806 AS-605240 0 3 72	8	3.181	Inf	0.923	0.011	0.57	0.923	2.81	0.936	0.000257	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
HCC1806	AZD8055	1	72	sigmoid	sigmoid	HCC1806 AZD8055 0 1 72	8	2.732	Inf	0.534	0.247	0.0515	0.522	1.19	0.995	1.3e-07	NA	0.521	0.484	0.716	0.0427	0.471	1.15	0.996	7.15e-08	NA
HCC1806	AZD8055	2	72	sigmoid	sigmoid	HCC1806 AZD8055 0 2 72	8	2.817	Inf	0.546	0.24	0.0517	0.535	1.19	0.995	1.31e-07	NA	0.521	0.484	0.716	0.0427	0.471	1.15	0.996	7.15e-08	NA
HCC1806	AZD8055	3	72	sigmoid	sigmoid	HCC1806 AZD8055 0 3 72	8	3.185	Inf	0.593	0.215	0.0523	0.583	1.19	0.995	1.36e-07	NA	0.521	0.484	0.716	0.0427	0.471	1.15	0.996	7.15e-08	NA
HCC1806	Dactolisib	1	72	sigmoid	sigmoid	HCC1806 dactolisib 0 1 72	8	2.743	0.135	-0.0744	0.444	0.391	-0.425	0.577	0.986	2.81e-06	NA	0.0977	0.121	0.559	0.093	0.0151	0.619	0.986	2.47e-06	NA
HCC1806	Dactolisib	2	72	sigmoid	sigmoid	HCC1806 dactolisib 0 2 72	8	2.828	0.145	-0.0528	0.433	0.401	-0.401	0.578	0.986	2.83e-06	NA	0.0977	0.121	0.559	0.0929	0.0151	0.619	0.986	2.47e-06	NA
HCC1806	Dactolisib	3	72	sigmoid	sigmoid	HCC1806 dactolisib 0 3 72	8	3.196	0.193	0.0324	0.393	0.437	-0.302	0.579	0.986	2.91e-06	NA	0.0977	0.121	0.559	0.093	0.0151	0.619	0.986	2.47e-06	NA
HCC1806	Buparlisib	1	72	sigmoid	sigmoid	HCC1806 buparlisib 0 1 72	8	2.742	0.748	-0.369	0.226	0.931	-0.415	2.75	1.0	2.95e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
HCC1806	Buparlisib	2	72	sigmoid	sigmoid	HCC1806 buparlisib 0 2 72	8	2.827	0.759	-0.346	0.221	0.937	-0.392	2.75	1.0	2.72e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
HCC1806	Buparlisib	3	72	sigmoid	sigmoid	HCC1806 buparlisib 0 3 72	8	3.195	0.808	-0.257	0.203	0.96	-0.303	2.74	1.0	2.03e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)